Estrogen Replacement Therapy and Ovarian Cancer

Background: A recent meta-analysis concluded that there was no overall association between estrogen replacement therapy (ERT) and risk of epithelial ovarian cancer. However, several subsequent studies have suggested that long-term ERT could increase ovarian cancer risk. Methods: We prospectively examined the association of ERT with epithelial ovarian cancer among 31,381 postmenopausal women in Iowa followed for 15 years. Results: Women who were using ERT at baseline had an elevated multivariate-adjusted relative risk of ovarian cancer (1.7; 95% confidence interval [CI] = 1.1–2.8) compared with never-users. Risk was higher among women who had been using ERT at baseline for more than 5 years (2.5; CI = 1.4–4.5). A time-dependent analysis likewise yielded a relative risk of 1.7 for current ERT use. Former ERT use was not associated with ovarian cancer incidence. Conclusions: Long duration of ERT use after menopause could increase the risk of epithelial ovarian cancer.

[1]  J. Weissfeld,et al.  Hormone replacement therapy formulations and risk of epithelial ovarian carcinoma. , 2002, Gynecologic oncology.

[2]  P. Hartge,et al.  Menopausal hormone replacement therapy and risk of ovarian cancer. , 2002, JAMA.

[3]  E. Weiderpass,et al.  Hormone replacement therapy and the risk of invasive epithelial ovarian cancer in Swedish women. , 2002, Journal of the National Cancer Institute.

[4]  T. Bäckström,et al.  Steroid receptors and hormones in relation to cell proliferation and apoptosis in poorly differentiated epithelial ovarian tumors. , 2001, International journal of oncology.

[5]  M. Thun,et al.  Estrogen replacement therapy and ovarian cancer mortality in a large prospective study of US women. , 2001, JAMA.

[6]  C. la Vecchia,et al.  Reproductive and hormonal factors and ovarian cancer. , 2001, Annals of oncology : official journal of the European Society for Medical Oncology.

[7]  S. Coughlin,et al.  A meta-analysis of estrogen replacement therapy and risk of epithelial ovarian cancer. , 2000, Journal of clinical epidemiology.

[8]  A. Whittemore,et al.  Declining ovarian cancer rates in U.S. women in relation to parity and oral contraceptive use. , 2000, Epidemiology.

[9]  R. Tarone,et al.  Age-period-cohort analyses of breast-, ovarian-, endometrial- and cervical-cancer mortality rates for Caucasian women in the USA. , 2000, Journal of epidemiology and biostatistics.

[10]  Shuk-Mei Ho,et al.  Expression of human estrogen receptor-α and -β, progesterone receptor, and androgen receptor mRNA in normal and malignant ovarian epithelial cells , 1999 .

[11]  S. Mok,et al.  Expression of human estrogen receptor-alpha and -beta, progesterone receptor, and androgen receptor mRNA in normal and malignant ovarian epithelial cells. , 1999, Proceedings of the National Academy of Sciences of the United States of America.

[12]  T. Sellers,et al.  Physical Activity, Waist‐to-Hip Ratio, and Other Risk Factors for Ovarian Cancer: A Follow‐up Study of Older Women , 1996, Epidemiology.

[13]  C. Longcope,et al.  Serum gonadotropins and steroid hormones and the development of ovarian cancer. , 1995, JAMA.

[14]  T. Sellers,et al.  Mortality and cancer rates in nonrespondents to a prospective study of older women: 5-year follow-up. , 1994, American journal of epidemiology.

[15]  A. Folsom,et al.  Association of Hormone-Replacement Therapy with Various Cardiovascular Risk Factors in Postmenopausal Women , 1993 .

[16]  J. Cerhan,et al.  Body fat distribution and 5-year risk of death in older women. , 1993, JAMA.

[17]  E. Diczfalusy,et al.  Effect of orally administered oestrogens on gonadotrophin levels in post-menopausal women. , 1989, Maturitas.

[18]  D. Kennedy,et al.  Prescribing of noncontraceptive estrogens and progestins in the United States, 1974-86. , 1988, American journal of public health.

[19]  A. Folsom,et al.  Accuracy and reliability of self-measurement of body girths. , 1988, American journal of epidemiology.

[20]  D. Cramer,et al.  Determinants of ovarian cancer risk. II. Inferences regarding pathogenesis. , 1983, Journal of the National Cancer Institute.

[21]  L. Wallentin,et al.  SERUM FSH, LH AND OESTRONE LEVELS IN POSTMENOPAUSAL PATIENTS ON OESTROGEN THERAPY , 1978, British journal of obstetrics and gynaecology.

[22]  B. Stadel.  The etiology and prevention of ovarian cancer , 1975 .

[23]  R. Drury,et al.  International Histological Classification of Tumours , 1973 .

[24]  M F Fathalla,et al.  Incessant ovulation--a factor in ovarian neoplasia? , 1971, Lancet.